Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Maternity
  4. Back
  5. Antenatal, general
  6. Home Blood Pressure and Urinalysis Monitoring, Obstetrics (931)
May 2025 RDS newsletter now available. Expand this announcement to view.

Welcome to the May 2025 update from the RDS team

1.     RDS deployments

Three small-scale releases took place during April and May, including the following fixes and improvements:

  • Applying moderate severity security patch to Umbraco.
  • Fixes to:
    • Random ordering of tiles on mobile app
    • Simultaneous issuing of multiple copies of content review alerts
    • Content display on mobile app for the left hand menu navigation option
  • Whitelisting of Jotforms outcomes pages so that recommendations for action can be displayed following completion of a form or calculation.

2.     RDS performance

Two short outages took place on the mornings of 12th and 22nd May. Tactuum is still investigating the root cause and will report on this shortly.

3.     Redesign of Gentamicin and Vancomycin calculator interfaces

New designs have been produced which make the health board name and calculator title clear to the user on these calculator pages, with a warning message and link to ensure users access the right calculator for their board. These designs have been implemented in a test environment and are now under review.

4.     RDS Redesign, archiving and version control

We now plan to release at end of July 2025 the following major enhancements:  redesigned Right Decision Service homepage, new search and browse interface, upgraded archiving and version control, and capability to edit content adopted from the Shared Content Library. We will provide slides and demos in advance of the release to introduce users and editors to the new functionality.

5. Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Monday 16 June 12.30-1.30 pm
  • Tuesday 24 June 3.45-4.45 pm

Running usage statistics reports using Google analytics

  • Wednesday 11th June: 2-3pm

 To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

6.New RDS toolkits

The following toolkits were launched during March 2025:

7.New RDS developments

Work is progressing on a number of decision support systems that are part of the wider Right Decision Service platform, beyond the web and mobile apps:

  • The Patient Reported Outcome Measures system. A minimum viable product version will be available for functional testing by key stakeholders at end of July.
  • Pharmacogenomics decision support as an extension of the current high risk prescribing decision support integrated with primary care electronic health record systems. This is part of a European research and innovation project.
  • Planned Date of Discharge decision support system to be tested in NHS Lanarkshire. Will undergo user acceptance testing in July with a view to piloting from November.

8. Implementation projects

Public library services in Inverclyde, East Renfrewshire, Glasgow Life, Angus, Falkirk and Stirling have come forward to work with the RDS team, the Scottish Library and Information Council and local Realistic Medicine leads, to develop their role in engaging citizens in Realistic Medicine. This includes promoting the Being a partner in my care app: Realistic Medicine Together. This provides tools and resources to support conversations about what matters to the person,  shared decision-making and self-management.

 

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

 

 

 

Home Blood Pressure and Urinalysis Monitoring, Obstetrics (931)

Warning
Please report any inaccuracies or issues with this guideline using our online form

Introduction

Raised blood pressure (BP) affects approximately 10% of pregnancies worldwide; almost half of these women develop pre-eclampsia. Globally, around 15% of maternal mortality is due to preeclampsia so early detection and prevention are paramount. 

The COVID-19 pandemic has required the NHS to urgently consider self-monitoring of BP at home by pregnant women in order to safely reduce the number of face-to-face consultations for pregnant and postnatal women. 

Self-monitoring of BP at home by pregnant women can either be used to replace measurement of blood pressure by a healthcare professional on the day of a scheduled clinic (i.e. intermittently) or can be done routinely and more frequently by pregnant women (e.g. daily or weekly) in addition to usual care.

Which women are eligible for Home BP monitoring?

Self-monitoring of blood pressure by pregnant women is going to be rolled out in phases to high-risk women.   Home monitoring will be initially targeted to women at high-risk of hypertensive complications or who are ‘shielded’ because of serious underlying medical conditions (Group 1), followed by women identified at increased risk of hypertensive complications (Group 2). 

Home blood pressure monitoring should NOT replace any appointment where a woman is receiving clinical review for her underlying medical condition (e.g. for respiratory review of cystic fibrosis or cardiac review of underlying cardiac condition) or where fetal assessment is required as part of the clinical review. 

All requests for home BP monitoring in GGC must be discussed and approved by a consultant.  The named consultant must have recorded in BadgerNet that they agree to home monitoring and outline the follow-up plan.

Group 1
Women identified as 'high risk' of hypertensive complication including: 

  • Chronic Hypertension
  • Current Gestational Hypertension (Pregnancy Induced Hypertension, PIH)
  • Current Pre-eclampsia

Women who have been advised to shield because of serious underlying medical conditions:

  • Cystic Fibrosis
  • Solid organ transplant
  • Cardiac conditions

Group 2
'Increased risk' of developing Pre-eclampsia

  • Hypertensive disease during a previous pregnancy
  • Chronic Kidney Disease
  • Autoimmune disease (eg SLE / Antiphospholipid syndrome)

All women being considered for home blood pressure monitoring must fulfil the following clinical inclusion and exclusion criteria: 

Inclusion criteria

  • Systolic BP range ≤140 mmHg
  • Diastolic BP range ≤100 mmHg
  • Proteinuria ≤ 1+ on urine dipstick
  • Normal full blood count, liver and renal function blood tests as baseline and when new proteinuria present

Exclusion criteria

  • Maternal age <16 years at booking.
  • Systolic BP >140 mmHg
  • Diastolic BP >100 mmHg
  • Proteinuria ≥ 2+ on urine dipstick
  • Symptoms of headaches, visual symptoms, epigastric pain
  • Significant mental health concerns
  • Women who are not capable of giving informed consent
  • Women who are not able to operate home blood pressure equipment
  • Fetal growth restriction
  • Women not wishing to take this responsibility

Eligibility should be considered on an individual basis for each woman, and in context of other pregnancy care guidance.   Consideration should be given to ensuring that the woman has sufficient digital literacy, data/internet and devices to participate in remote consultations.

Clinical Pathway

  1. Arrange for a woman to attend face to face appointment in Daycare Unit. Ask her to bring her mobile phone with her to the appointment. If a woman already has a blood pressure monitor at home, all NHS-issued monitors are validated. If she owns her own device, ask her to bring it to the appointment so the obstetrician can check it is suitable for use in pregnancy. 

  2. Provide antenatal or postnatal check as usual. Assess eligibility to participate in self-monitoring of blood pressure and urinalysis. Ensure contact details are up to date on BadgerNet (home, mobile phone, number, and email).

  3. Provide an NHS device and an appropriately sized cuff (check upper arm measurement). In some cases, proxy measures may be taken from the forearm. Complete a blood pressure monitor loan form with the woman, ensuring the asset is appropriately labelled and tracked and informed consent is given.

  4. If a woman has brought her own blood pressure monitor to the appointment, validate it as suitable for pregnancy and puerperium. The following are validated monitors:

  1. Give written instructions on how to take a blood pressure reading (patient information leaflet) and signpost the link to the short video: British Heart Foundation - How to take your own blood pressure. Use teach-back to show the woman how to take her own blood pressure, write down and interpret her results. Ask the woman to take her blood pressure by herself twice, at least one minute apart, to demonstrate understanding (patient information leaflet).

  2. Give written instructions on how to self-monitor for proteinuria and glycosuria (patient information leaflet). As above, use teach-back to ensure the woman understands how to use the test and where and how to record her results.

Glycosuria detected by routine antenatal testing: be aware that glycosuria of 2+ or above on 1 occasion or of 1+ or above on 2 or more occasions detected by reagent strip testing during routine antenatal care may indicate undiagnosed gestational diabetes. If this is observed, consider further testing to exclude gestational diabetes.  

  1. Give written instructions on expected frequency of blood pressure monitoring and urinalysis, making clear whether this will be done in place of usual care (e.g. on the morning of a scheduled telephone/ virtual clinic appointment) or in addition to usual care (e.g. once a week, three times a week etc).

  2. Make clear home-readings will not be reviewed by a healthcare professional unless it is before a pre-organised clinic appointment or virtual contact. Women should be discouraged from recording readings at unspecified times.  However, ensure she understands who to contact if she is concerned.  
  3. If a woman requires additional investigations / appointments (e.g. growth scan, obstetric clinic follow-up etc), arrange as per local guidelines.

  4. Provide a paper blood pressure recording diary and show her how to use it.

  5. Please inform the woman that it is vital that they follow the written instructions and phone the hospital contact number if they develop raised blood pressure, new proteinuria, increasing proteinuria, or new symptoms.

  6. Book the next appointment with the woman and discuss whether this will be telephone (or other remote working) or face-to-face. A robust plan must be documented in BadgerNet for named consultant review in some format.

  7. Inform the GP that the woman is undertaking home blood pressure monitoring.

  8. Explain the arrangements to the woman for the return of the blood pressure monitor (local arrangements). Once returned, wipe the blood pressure monitor thoroughly with a cleaning wipe, and check that all components are correct.

How to interpret home monitoring

An overview of home blood pressure monitoring

Editorial Information

Last reviewed: 14/05/2020

Next review date: 23/05/2024

Author(s): Janet Brennand.

Version: 2

Approved By: Obstetrics Clinical Governance Group

Document Id: 931